Quarterly report · Q2
4978.TEDINET S100PIAG
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥989m | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | −¥90m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | −¥359m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥70m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥507m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥202m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥70m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥202m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥69m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥575m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥202m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥69m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | −¥202m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥8.8bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥8.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥6.6bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥970m | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥845m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥61m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥246m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥140m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥541m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥979m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥485m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥686m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.82 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.31 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.79 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.09 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment ordinary income | 2022-04-01 → 2022-09-30 | −¥286m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥674m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥674m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | segment ordinary income | 2022-04-01 → 2022-09-30 | ¥222m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥903m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥903m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | segment ordinary income | 2022-04-01 → 2022-09-30 | ¥134m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| —segment total | segment ordinary income | 2022-04-01 → 2022-09-30 | ¥356m |
| Reconciling Itemsreconciling | segment ordinary income | 2021-04-01 → 2021-09-30 | −¥251m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥369m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥369m |
| jpcrp040300-q2r_E27585-000Medical Businessreportable segment | segment ordinary income | 2021-04-01 → 2021-09-30 | −¥23m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥621m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥621m |
| jpcrp040300-q2r_E27585-000Research Support Businessreportable segment | segment ordinary income | 2021-04-01 → 2021-09-30 | ¥72m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥989m |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥989m |
| —segment total | segment ordinary income | 2021-04-01 → 2021-09-30 | ¥49m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -649000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 308000 | JPY |
| Compensations sga | Prior1YTDDuration | 49884000 | JPY |
| Compensations sga | CurrentYTDDuration | 45952000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 620504000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 368577000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 989082000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 989082000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 620504000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 368577000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 989082000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 989082000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 72159000 | JPY |
| Ordinary income | Prior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | -22892000 | JPY |
| Ordinary income | Prior1YTDDuration_ReportableSegmentsMember | 49266000 | JPY |
| Ordinary income | Prior1YTDDuration_ReconcilingItemsMember | -250842000 | JPY |
| Ordinary income | Prior1YTDDuration | -201576000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 902728000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 674028000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 1576757000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1576757000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 902728000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 674028000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 1576757000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 1576757000 | JPY |
| Ordinary income | CurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember | 134355000 | JPY |
| Ordinary income | CurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember | 221863000 | JPY |
| Ordinary income | CurrentYTDDuration_ReportableSegmentsMember | 356218000 | JPY |
| Ordinary income | CurrentYTDDuration_ReconcilingItemsMember | -286100000 | JPY |
| Ordinary income | CurrentYTDDuration | 70118000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-09 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社リプロセル |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |